title: A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
abstract: A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Positive evidence from randomised trials has been lacking, and the British National Lymphoma Investigation therefore commenced a randomised comparison of CHOP vs a third-generation regimen, PACEBOM, in November 1987. A total of 459 eligible patients were entered into the trial: 226 in the CHOP arm and 233 in the PACEBOM arm. Overall, there was no significant difference in outcome between the two arms of the trial. In patients with stage IV disease there was an apparent improvement in survival for those treated with PACEBOM, but considerable caution must be exercised with such subgroup analysis.
authors.affiliation: Department of Haematology and Oncology, University College London Medical School (UCLMS), UK.
authors.forename: D C
authors.initials: DC
authors.lastname: Linch
authors.forename: B
authors.initials: B
authors.lastname: Vaughan Hudson
authors.forename: B W
authors.initials: BW
authors.lastname: Hancock
authors.forename: P J
authors.initials: PJ
authors.lastname: Hoskin
authors.forename: D C
authors.initials: DC
authors.lastname: Cunningham
authors.forename: A C
authors.initials: AC
authors.lastname: Newland
authors.forename: D W
authors.initials: DW
authors.lastname: Milligan
authors.forename: P A
authors.initials: PA
authors.lastname: Stevenson
authors.forename: J K
authors.initials: JK
authors.lastname: Wood
authors.forename: K A
authors.initials: KA
authors.lastname: MacLennan
authors.forename: L
authors.initials: L
authors.lastname: Anderson
authors.forename: W M
authors.initials: WM
authors.lastname: Gregory
authors.forename: G
authors.initials: G
authors.lastname: Vaughan Hudson
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone; D008727:Methotrexate